|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rimas Orentas, PhD, and Boro Dropulić, PhD, MBA, believe the future belongs to those who will be able to innovate rapidly, maintain regulatory confidence, and drive down costs to make CAR-T cell and other engineered cell therapies available to all who would benefit.
|
|
|
Giles Campion, MD, says while the liver offers plenty of fertile ground for developing siRNAs therapies to treat many diseases, many disease-related genes are not highly expressed in the liver. For this reason, the next great challenge in the field is delivering siRNA to tissues outside the liver.
|
|
|
Thomas Donner, MD, explains how advances in stem-cell engineering, immune-evasion technologies, and vascularization of implanted cells have the potential to generate novel therapeutics that could lead to reduced treatment burden for patients with T1D and infuse new energy into efforts at finding a cure.
|
|
|
Bill Vincent believes if the industry wants to keep moving up the steep growth curve, then capacity and raw materials must be readily available. The innovations in therapies, platforms, and processes will all come with time, money, and increasing availability of resources.
|
|
|
|
|
|
|
|
|

Gerresheimer is the global partner for pharmaceutics, biotech, healthcare, and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging solutions and drug delivery systems. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and concentration on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Click here for more.
|
|
|
|
|
|
 |
|
Excision BioTherapeutics, Inc. recently announced the first participant has been dosed in the Phase 1/2 clinical trial of EBT-101 for human immunodeficiency virus type 1 (HIV-1)…..
|
|
 |
|
RQM+ recently announced the acquisition of Jordi Labs. With these new capabilities, RQM+ provides comprehensive regulatory, quality, clinical, and laboratory services, supporting market….
|
|
 |
|
Cidara Therapeutics, Inc. recently announced the initiation of its Phase 2a trial to evaluate the pre-exposure prophylactic activity of CD388 against influenza virus…..
|
|
 |
|
BD (Becton, Dickinson and Company) recently introduced a next-generation glass prefillable syringe (PFS) that sets a new standard in performance for vaccine PFS with new and….
|
|
|
|
|
|
|
|
 |
|
In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.
|
|
 |
|
Emergent and groniger partner to present the benefits and features of the INTEGRA® high-speed aseptic fill line with isolator technology for viral vaccines and therapeutics.
|
|
|
|
|
|
|
|
 |
|
Synchronizing and controlling API delivery, Extrusion-Spheronization (E-S) offers pharmaceutical drug developers a robust technique to develop and manufacture today’s most complex oral sold dose therapeutics.
Manufacturing oral solid dose API’s into spheres via Extrusion-Spheronization is not new. What is …
|
|
 |
|
In today’s fast-growing biopharma market, injectable medications have become a powerful driver of growth and innovation. Within that sector, industry leaders are increasingly focused on one key area: integrating a drug product and a delivery device. As the market expands …
|
|
|
|
|
Upcoming eNewsletter Features:
September 28 – API Synthesis
October 5 – Bioavailability
|
|
|
|
|
|
|
|